今日港股继续走强，恒指向上突破2022年以来新高，截至收盘，恒指、恒科指分别收涨0.54%、 0.38%。创新药走势活跃，高纯度+高弹性标的港股通创新药ETF（520880）早盘场内价格一度冲高涨逾 3%，再刷上市以来新高，午后震荡回落，收涨0.17%，全天成交额2.43亿元，环比放量47%。 | 序号 | 代码 | 名称 | 两日图 | 现价 | 涨跌 | 涨跌幅 ▼ | | --- | --- | --- | --- | --- | --- | --- | | 1 | 1513 | 丽珠医药 | Value | 39.700 | 3.400 | 9.37% | | 2 | 9688 | 更開医药 | | 29.500 | 2.150 | 7.86% | | 3 | 3933 | 联邦制药 | | 16.400 | 0.980 | 6.36% | | 4 | 9926 | 康方生物 | | 147.000 | 6.500 | 4.63% | | 5 | 1548 | 金斯瑞生物科技 | Ram | 17.020 | 0.600 | 3.65% | | 6 | 3320 | 华润医药 | Value Vir ...

港股今早冲高回落，临近午盘，三大指数再度发力走高，恒指成功站上两万五大关。截止收盘，恒生指 数涨0.54%或135.89点，报25130.03点，全日成交额为2660.73亿港元；恒生国企指数涨0.39%，报9075.6 点；恒生科技指数涨0.38%，报5606.83点。 华泰证券认为，港股三季度市场或依然高波动，但压力因素比预期更低，行情启动时点可能更早。外部 新一轮关税谈判下中国相对优势反而上升；美国金融去监管、联储继续降息、稳定币扩容、国债久期调 整等多重因素助力下，美元指数有进一步下行空间，人民币升值利好港股表现；内部"反内卷"加码、互 联网电商负面压力减轻以及房地产政策都有一定积极变化。 蓝筹股表现 比亚迪（002594）股份(01211)表现亮眼。截至收盘，涨5.09%，报134.2港元，成交额48.28亿港元，贡 献恒指37.78点。7月21日，比亚迪在深汕工厂举行第1300万辆新能源汽车下线仪式，超级四电旗舰轿车 仰望U7作为下线车型亮相。2025年上半年，比亚迪汽车销量稳步攀升，今年1-6月，比亚迪国内销量超 211.3万，同比增长31.5%；同期海外销量47.2万，同比增长128.5%。 ...

证券代码：000513、01513 证券简称：丽珠集团、丽珠医药 公告编号：2025-050 丽珠医药集团股份有限公司 关于重组抗人IL-17A/F人源化单克隆抗体注射液Ⅲ期临床试验 达到主要研究终点的提示性公告 本公司及董事会全体成员保证信息披露内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 丽珠医药集团股份有限公司（以下简称"本公司"）控股附属公司珠海市丽珠 单抗生物技术有限公司（以下简称"丽珠单抗"）与北京鑫康合生物医药科技有限 公司联合开发的"重组抗人 IL-17A/F 人源化单克隆抗体注射液"（以下简称 "LZM012"或"本品"）的Ⅲ期临床试验达到主要研究终点。现将有关详情公告如 下： 一、药品基本情况 药品名称：重组抗人 IL-17A/F 人源化单克隆抗体注射液 英文名/拉丁名：Recombinant anti-human IL-17A/F Humanized Monoclonal 剂型：注射剂 规格：160 mg（1.6mL）/瓶 注册分类：治疗用生物制品 1 类 上市申请人：珠海市丽珠单抗生物技术有限公司 二、临床试验相关情况 该Ⅲ期临床研究是一项在中重度斑块型银屑病患者中开展 ...

智通财经APP获悉，港股今日冲高回落，三大指数午后集体转跌。截止收盘，恒生指数跌0.29%或72.36 点，报24517.76点，全日成交额为2589.51亿港元；恒生国企指数跌0.18%，报8861.39点；恒生科技指数 跌0.24%，报5418.4点。 申万宏源表示，持续看好港股以及A股市场的投资机会，在未来全球金融秩序重构的过程中，中国香港 将扮演重要角色，港股优质资产繁荣度预计不断提升，成为本土在岸资金+全球新秩序下的核心资本市 场。 蓝筹股表现 安踏体育(02020)领涨蓝筹。截至收盘，涨2.28%，报91.85港元，成交额13.2亿港元，贡献恒指4.55点。 安踏体育公布，2025年二季度，安踏品牌、FILA品牌流水分别同比增长低单位数、中单位数，所有其 他品牌流水同比增长50-55%。上半年， 安踏、FILA、其他品牌零售金额同比分别取得中单位数、高单 位数、60-65%的正增长。 其他蓝筹股方面，快手-W(01024)涨2.13%，报69.6港元，贡献恒指6.9点；携程集团-S(09961 )涨1.59%， 报498.2港元，贡献恒指3.36点；申洲国际(02313)跌2.75%，报56.6港 ...

Key Points - A total of 133 stocks reached their 52-week highs as of July 16, with notable performers including 威雅利 (00854) at 909.12%, 绿心集团股权 (02999) at 135.29%, and 首都金融控股 (08239) at 65.22% [1] - 威雅利 (00854) closed at 12.660, with a peak price of 33.200, marking a significant increase of 909.12% [1] - 绿心集团股权 (02999) had a closing price of 0.020 and reached a high of 0.040, reflecting a growth of 135.29% [1] - 首都金融控股 (08239) closed at 1.590, with a maximum price of 1.900, indicating a rise of 65.22% [1] - Other notable stocks include 中国三三传媒 (08087) with a 59.54% increase, and 云能国际 (01298) with a 41.23% increase [1] - The report also lists stocks that reached their 52-week lows, with 百利达集团控股 (08179) at -7.14% and 昊天国际建投 (01341) at -6.28% [5]

Group 1 - The core viewpoint of the news is the significant performance and growth of the Hong Kong Innovative Drug ETF, which has seen a cumulative increase of over 100% in the past year, reflecting strong investor interest in the innovative drug sector [1][2] - As of July 15, 2025, the Hong Kong Innovative Drug ETF has a net asset value increase of 108.39% over the past year, ranking 1st out of 122 QDII equity funds, indicating its strong performance relative to peers [2] - The Hong Kong Innovative Drug ETF closely tracks the CSI Hong Kong Innovative Drug Index, which includes up to 50 listed companies primarily engaged in innovative drug research and development, providing a comprehensive view of the sector's performance [2] Group 2 - Recent measures introduced by the National Healthcare Security Administration and the National Health Commission aim to support the high-quality development of innovative drugs, including increased R&D support and inclusion in insurance directories [3] - The current market rally in Hong Kong's innovative drug sector is driven by a revaluation of value, with expectations for a new commercial insurance directory for innovative drugs to be launched in 2025, potentially creating a more favorable pricing environment [3] - The Hong Kong Innovative Drug ETF supports T+0 trading, enhancing liquidity and allowing investors to conduct multiple transactions within a trading day, thereby improving capital efficiency [3]

Group 1 - The Hong Kong pharmaceutical sector is experiencing positive momentum, with notable stock increases for companies such as Lijun Pharmaceutical (up over 13%), Green Leaf Pharmaceutical, and Fosun Pharmaceutical (both up over 8%) [1] - The State Medical Insurance Administration and the National Health Commission have introduced measures to support the high-quality development of innovative drugs, focusing on issues faced by the innovative drug sector and proposing 16 measures across five areas [1] - The measures aim to provide comprehensive support for the entire chain of innovative drug development, including research, market access, hospital usage, and diversified payment methods, emphasizing genuine support for innovation [1] Group 2 - Guoyuan Securities highlights the importance of increasing the commercial insurance innovative drug directory, indicating a strengthened role for commercial insurance in the multi-tiered medical security system, which is a significant step for market access [2] - The ongoing reform of medical insurance payment methods by the National Medical Insurance Administration is expected to create broader opportunities for commercial insurance, enhancing its flexibility and supplementary role in supporting high-priced innovative drugs and medical devices [2] - The aging population in China is driving a rigid growth in demand for pharmaceuticals and healthcare services, particularly among the elderly who face multiple chronic diseases, thus expanding the pharmaceutical market [2] Group 3 - The Chinese pharmaceutical industry has maintained steady growth, demonstrating resilience even during challenging economic conditions, with a notable anti-cyclical consumption pattern [3] - The increasing elderly population is not only raising the demand for basic medications but also creating a need for specialized treatments, rehabilitation care, and health monitoring services, providing ample opportunities for the development of niche markets within the pharmaceutical sector [3] - The demand growth driven by demographic changes is characterized by long-term stability, serving as a core driver for the sustained development of the pharmaceutical industry [3]

Group 1: Market Performance - The innovative drug sector in both A-shares and Hong Kong stocks experienced significant gains, with A-shares seeing a surge in stock prices, including Lianhuan Pharmaceutical achieving six consecutive trading limits within eight days [1][4] - Notable A-share stocks include Guangshentang rising over 16% and Wuwei Biological increasing nearly 15% [1][2] - In the Hong Kong market, Lijuzhiyuan led with a rise of over 13%, while other companies like Green Leaf Pharmaceutical and Fosun Pharma also showed strong performance [2][3] Group 2: Policy Support - The recent surge in the innovative drug sector is attributed to favorable policy releases, particularly the exclusion of innovative drugs from the latest round of centralized procurement, which alleviated concerns about profit margins being squeezed [4][6] - The National Healthcare Security Administration's initiation of the 2025 medical insurance drug catalog adjustment, which includes a new commercial insurance catalog for innovative drugs, further supports the sector by broadening payment channels [6][7] Group 3: Financial Performance - Leading companies in the sector are reporting strong financial results, with WuXi AppTec expecting a revenue of approximately 20.8 billion yuan, a year-on-year increase of 20.64%, and a net profit of about 6.3 billion yuan, up 44.43% [7] - Other companies like Ganli Pharmaceutical and Zhongsheng Pharmaceutical are also projecting significant profit increases, with Ganli's net profit expected to rise by 100.73% to 114.12% [7][8] Group 4: International Expansion - Chinese innovative drug companies are accelerating their international expansion, with notable deals such as the $60.5 billion authorization agreement between 3SBio and Pfizer, highlighting the global competitiveness of Chinese innovative drugs [8][9] Group 5: Future Outlook - Institutions maintain an optimistic long-term outlook for the innovative drug market, with Goldman Sachs noting that the overall market capitalization of Chinese biotech companies is still only 14%-15% of their U.S. counterparts, indicating a potential for value re-evaluation [9] - The innovative drug sector is expected to continue its upward trend, supported by policy backing and increasing global competitiveness, with a focus on selecting stocks post-rebound [9]

Group 1 - The Hong Kong stock market for innovative drug concept stocks has seen a resurgence, with notable increases in share prices for several companies [1] - Lijun Pharmaceutical surged over 14%, while Green Leaf Pharmaceutical rose over 9%, and Fosun Pharma (600196) increased nearly 8% [1] - Other companies such as Kangfang Biotech and Lianbang Pharmaceutical also experienced gains of nearly 5% [1] Group 2 - Investors can buy Hong Kong stocks through A-share accounts without the need for the Hong Kong Stock Connect, allowing for T+0 trading [1]

Economic Overview - The domestic GDP for the first half of the year reached 660,536 billion yuan, showing a year-on-year growth of 5.3% [1] - The primary industry added value was 31,172 billion yuan, growing by 3.7%; the secondary industry added value was 239,050 billion yuan, with a growth of 5.3%; and the tertiary industry added value was 390,314 billion yuan, increasing by 5.5% [1] Market Performance - The CSI 500 Quality Growth Index (930939) increased by 0.17%, with notable stock performances including LIZHU Group (000513) up by 6.71% and KEDALI (002850) up by 6.43% [1] - The CSI 500 Quality Growth ETF (560500) is showing positive momentum, currently priced at 1 yuan [1] Policy Insights - Everbright Securities noted that domestic policies have shifted towards a focus on fundamentals and liquidity since September of last year, maintaining a positive stance despite some restraint [1] - The flexibility and foresight of policy measures are expected to stabilize market expectations and promote healthy capital market development [1] Investment Opportunities - According to Shenwan Hongyuan Securities, the A-share market is accumulating positive factors, with the CSI 500 Quality Growth Index's valuation at a historical low, with a latest price-to-book ratio (PB) of 1.9 times, below 88.94% of the past three years [2] - The CSI 500 Quality Growth Index selects 100 companies with high profitability, sustainable earnings, and strong cash flow from the CSI 500 Index, providing diverse investment options [2] Top Holdings - As of June 30, 2025, the top ten weighted stocks in the CSI 500 Quality Growth Index accounted for 20.42% of the index, including Dongwu Securities (601555) and Kaiying Network (002517) [2]